First-in-human gene editing for lipid lowering: the initial results

Simon Tual-Chalot,Konstantinos Stellos

DOI: https://doi.org/10.1093/cvr/cvae037

IF: 13.081

2024-03-31

Cardiovascular Research

Abstract:Atherosclerotic cardiovascular disease (ASCVD) is characterized by a build-up of plaque inside the arteries due to a chronic slowly evolving vascular wall inflammation and lipid accumulation that can lead to several major adverse cardiovascular events including myocardial infarction, stroke, or even death. Because the relative risk for major adverse cardiovascular events is decreased when low-density lipoprotein cholesterol (LDL-C) levels in blood are reduced, 1 the European Society of Cardiology guidelines, along with other international directives, advocate the use of lipid-lowering statins therapy as a primary preventive measure for ASCVD in individuals exhibiting pathologically elevated levels of LDL-C in blood. 2 However, the low adherence to statin therapies, marked by rates falling below 50% within the first year of initiation and further declining to 30% by the second year, is linked to an increased risk of mortality. 2 The statin discontinuation, attributable to patient choice, lack of sufficient beneficial effect or tolerance, highlights the need for alternative therapies.

cardiac & cardiovascular systems